Table 3. Hazard ratios (HRs) and 95% confidential intervals (CIs) for Overall survival (OS).

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age		0.001		0.042
>35	1		1
≤35	0.429(0.260–0.708)		0.536(0.325–0.978)
T stage		<0.001		0.073
1	1		1
2	1.677(0.995–2.828)	0.052	1.340(0.763–2.355)
3	5.751(2.836–11.662)	<0.001	2.123(0.955–4.718)
N stage		<0.001		<0.001
0	1		1
1	1.460(0.845–2.524)	0.175	1.128(0.619–2.053)
2	3.847(2.086–7.093)	<0.001	2.894(1.483–5.648)
3	6.566(3.672–11.741)	<0.001	4.067(2.027–8.162)
LVI		<0.001		0.116
Negative	1		1
Positive	3.079(1.833–5.172)		1.595(0.891–2.856)
HG		0.492
I and II	1
III	1.080(0.867–1.344)
A20		<0.001		<0.001
Low	1		1
High	2.906(1.801–4.690)		2.629(1.585–4.361)
ER		0.292
Negative	1
Positive	0.793(0.515–1.221)
PR		0.330
Negative	1
Positive	0.808(0.526–1.241)
HER2		0.831
Negative	1
Positive	0.934(0.497–1.754)
TNBC vs non-TNBC		0.857
Non-TNBC	1
TNBC	1.045(0.645–1.693)

LVI, Lymphovascular invasion; HG, histologic grade; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; TNBC, triple negative breast cancer